NF-κB: A therapeutic target in inflammatory diseases

Expert Opinion on Therapeutic Targets

Volumn 5, Issue 2, 2001, Pages 197-204

  Curran, Christine L ^a   Blackwell, Timothy S ^a   Christman, John W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti oxidants; corticosteroids; inflammation; proteosome

Indexed keywords

EID: 33745511403     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.5.2.197     Document Type: Review

References (56)

1. KARIN M, BEN-NERIAH Y: Phosphorylation meets ubiquitination: the control of NF-KB activity. Ann. Rev. Immunol. (2000) 18:621-663.
2. SEN R, BALTIMORE D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell (1986) 46:705-716.
3. SHA WC: Regulation of immune responses by NF-KB/Rel transcription factors. J. Exp. Med. (1998) 187 (2):143-146.
4. KUNSCH C, RUBEN SM, ROSEN CA: Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol. Cell Biol. (1992) 12:4412-4421.
5. GORLICH D, MATTAJ IW: Nucleocytoplasmic transport. Science (1996) 271:1513-1518.
6. KARIN M, DELHASE M: The IKB kinase (IKK) and NF-KB: key elements of proinflammatory signaling. Semin. Immunol. (2000) 12:85-98.
7. DELHASE M, HAYAKAWA M, CHENY, KARIN M: Positive and negative regulation of IKB kinase activity through IKK|5 subunit phosphorylation. Science (1999) 284:309-313.
8. KARIN M: The beginning of the end: IKB kinase (IKK) and NF-KB activation. J. Biol. Chem. (1999) 274(39):27339-27342.
9. ROTHWARF DM, ZANDI E, NATOLI G, KARIN M: IKK-yis an essential regulatory subunit of the IKB kinase complex. Nature (1998) 395:297-300.
10. PAHL HL: Activators and target genes of Rel/NF-KB transcription factors. Oncogene (1999) 18:6853-6866.
11. SCHWARTZ MD, MOORE EE, MOORE FA et al.: Nuclear-factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit. Care Med. (1996) 24:1285-1292.
12. MOINE P, McINTYRE R, SCWARTZ MD et al: NF-kappa B regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. Shock (2000) 13:85-91.
13. CHRISTMAN JW, VENKATAKRISHNAN A, WHEELER AP, BERNARD GR, BLACKWELL TS: NF-KB binding activity in mixed BAL cells from patients with SIRS and ARDS. Sepsis (2000) 4:35-41.
14. BOHRER H, QIU F, ZIMMERMANN T et al: Role of NF-KB in the mortality of sepsis. J. Clin. Invest. (1997) 100:972-985.
15. PATERSON RL, GALLEY HF, DHILLON JK, WEBSTER NR: Increased nuclear factor kappa B activation in critically ill patients who die. Crit. Care Med. (2000) 28:1047-1051.
16. ARNALICH F, GARCIA-PALOMERO E, LOPEZ J et al: Predictive value of nuclear factor kappa B activity and plasma cytokine levels in patients with sepsis. Infect. Immun. (2000) 68:1942-1945.
17. ADIB-CONQUY M, ADRIE C, MOINE P et al: NF-KB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am. J. Respr. Crit. Care Med. (2000) 162:1877-1883.
18. SCHREIBER S, NIKOLAUS S, HAMPE J: Activation of nuclear factor KB in inflammatory bowel disease. Gut (1998) 42:477-484.
19. NEURATH MF, FUSS I, SCHURMANN G et al: Cytokine gene transcription by NF-KB family members in patients with inflammatory bowel disease. Ann. NY Acad. Sci. (1998) 859:149-159.
20. CAMPBELL IK, GERONDAKIS S, O'DONNELL K, WICKS IP: Distinct roles for the NF-KB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J. Clin. Invest. (2000) 105:1799-1806.
21. BONDESON J, FOXWELL B, BRENNAN F, FELDMANN M: Defining therapeutic targets by using adenovirus: blocking NF-KB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Natl. Acad. Sci. (1999) 96:5668-5673.
22. EPINAT JC, GILMORE TD: Diverse agents act at multiple levels to inhibit the Rel/NF-KB signal transduction pathway. Oncogene (1999) 18(49):6896-6909.
23. SCHRECK RK, ALBERMAN K, BAEUERLE PA: Nuclear factor KB: an oxidative stress-response transcription factor of eukaryotic cells. Free Radic. Res. Commun. (1992) 17:221-237.
24. MIROCHINITCHENKO O, INOUYE M: Effect of overex-pression of human Cu, Zn superoxide dismutase in transgenic mice onmacrophage functions. J. Immunol. (1996) 156:1578-86.
25. KONO H, RUSYN I, YIN M et al.: NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J. Clin. Invest. (2000) 106(7):867-872.
26. KOVACICH JC, BOYLE EM, MORGAN EN et al.: Inhibition of the transcriptional activator protein nuclear factor [kappa] B prevents hemodynamic stability associated with whole-body inflammatory response syndrome. J. Thorac. Cardiovasc. Surg. (1999) 118:154-162.
27. LAUZURICA P, MARTINEZ-MARTINEZ S, MARAZUELA M et al.: Pyrrolidine dithiocarbamate protects mice from lethal shock induced by LPS or TNF-α. Eur. J. Immunol. (1999) 29:1890-1900.
28. ROSS SD, KRON IL, GANGEMI JJ et al.: Attenuation of lung reperfusion injury after transplantation using an inhibitor of nuclear-factor kappaB. Am. J. Physiol. Lung Cell Mol. Physiol. (2000) 279(3):L528-536.
29. BLACKWELL TS, HOLDEN EP, BLACKWELL TR, CHRISTMAN BW, CHRISTMAN JW: Activation ofNF-κB in rat lungs by treatment with endotoxin: modulation by treatment with N-acetylcysteine. J. Immunol. (1996) 157:1630-1637.
30. BERNARD GR, WHEELER AP, ARONS MM et al.: A trial of anti-oxidants N-acetylcysteine and procysteine in ARDS. Chest (1997) 112:164-172.
31. BOWIE A, O'NEIL LAJ: Oxidative Stress and nuclear factor-κB activation. Areassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol. (2000) 59:13-23.
32. SCHENMAN RI, COGSWELL PC, LOFQUIST AK, BALDWIN AS: Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270:283-286.
33. AUPHAN N, DIDONATO JA, ROSETTE C, HELMBERG A, KARIN M: Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. (1995) Science 270:286-290.
34. DE BOSSCHER K, SCHMITZ ML, BERGHE WV, PLAISANCE S, FIERS W, HAEGEMAN G: Glucocorticoid-mediated repression of nuclear factor-κB-dependant transcription involves direct interference with transactivation. Proc. Natl. Acad. Sci. (1997) 94:13504-13509.
35. RAY A, PREFONTAINE KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc. Natl. Acad. Sci. (1994) 91:752-756.
36. HADDAD EB, SALMON M, KOTO H, BARNES PJ, ADCOCK I, CHUNG KF: Ozone induction of cytokine-induced neutrophil chemoattractant (CINC) and nuclear factor κb in rat lung: inhibition by corticosteroids. FEBS lett. (1996) 379:265-268.
37. SADIKOT R, JANSEN ED, BLACKWELL T et al.: High dose dexamethasone accentuates NF-κB activation in endotoxin-treated mice. (In Press).
38. LIN Y, BROWN K, SIEBENLIST U: Activation of NF-KB requires proteolysis of the inhibitor IKBa: signal induced phosphorylation of IKBa alone does not release active NF-KB. Proc. Natl. Acad. Sci. (1995) 92:552-556.
39. RUETTEN H, THIEMERMANN C: Effect of calpain inhibitor I, an inhibitor of the proteolysis of IKB, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br. J. Pharmacol. (1997) 121:695-704.
40. CUZZOCREA S, MCDONALD M, MAZZON E etal: Calpain inhibitor I reduces the development of acute and chronic inflammation. Am. J. Pathol. (2000) 157:2065-2079.
41. LANCASTER LH, CHRISTMAN JW, BLACKWELL TR, KOAY MA, BLACKWELL TS: Suppression of lung inflammation in rats by prevention of NF-KB activation in the liver. Inflamm. (In press)
42. KOPP E, GHOSH S: Inhibition of NF-KB by sodium salicylate and aspirin. Science (1994) 265:956-959.
43. YIN M, YAMAMOTO Y, GAYNOR RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of IKB kinase-P. Nature (1998) 396:77-80.
44. FRANTZ B, O'NEILl EA: The effect of sodium salicylate and aspirin on NF-KB. Science (1995) 270:2017-2018.
45. CASTRILLO A, DIAZ-GUERRA MJM, HORTELANO S, MARTIN-SANZ P, BOSCA L: Inhibition of IKB kinase and IKB phosphorylation by 15-Deoxy-A12, 14-prostaglandin J2 in activated murine macrophages. Mol. Cell Biol. (2000) 20:1692-1698.
46. ROSSI A, KAPAHL O, NATOLL G etal: Anti-inflammatory cyclopentanone prostaglandins are direct inhibitors of I kappa B kinase. Nature (2000) 403:103-108.
47. STRAUS DS, PASCUAL G, LI M et al.: 15-Deoxy-A12, 14-prostaglandin J2 in inhibits multiple steps in the NF-KB signaling pathway. Proc. Natl. Acad. Sci. (2000) 97:4844-4849.
48. HORTELANO S, CASTRILLO A, ALVAREZ AM, BOSCA L: Contribution of cyclopentanone prostaglandins to the resolution of inflammation through potentiation of apoptosis in activated macrophages. J. Immunol. (2000) 165:6525-6531.
49. BROCKMAN JA, SCHERER DC, MCKINSEY TA et al.: Coupling of signal response domain in IκBα to multiple pathways for NF-κB activation. Mol. Cell Biol. (1995) 15:2809-2818.
50. BALDI L, BROWN K,FRANZOSO G, SIEBENLIST U: Critical role for Lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of IκBα. J. Biol. Chem. (1996) 271:376-379.
51. LING L, CAO Z, GOEDDEL DV: NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. (1998) 95:3792-3797.
52. O'CONNELL MA, BENNETT BL, MERCURIO F, MANNING AM, MACKMAN N: Role of IKK1 and IKK2 in lipopoly-saccharide signaling in human monocytic cells. J. Biol. Chem. (1998) 273:30410-30414.
53. LIN Y, YAO S, VEACH RA, TORGERSON TR, HAWIGER J: Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. (1995) 270(24):14255-144258.
54. LIU X, ROBINSON D, VEACH RA et al.: Peptide-directed suppression of a pro-inflammatory cytokine response. J. Biol. Chem. (2000) 275(22):16774-16778.
55. FUJIHARA S, CLEAVELAND J, GROSMAIRE L et al.: A D-amino acid peptide inhibitor of NF-κB nuclear localization is efficacious in models of inflammatory disease. J. Immunol. (2000) 165:1004-1012.
56. MAY MJ, D'ACQUISTO F, MADGE LA et al.: Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science (2000) 289:1550-1554.